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ABSTRACT 
Chronic kidney disease (CKD) is associated with high healthcare costs, poor health outcomes 
and low quality of life (Donald et al., 2018). The US CKD prevalence is 15%, costing Medicare 
$79 billion in 2016 (United States Renal Data System, 2018). Self-management could reduce 
CKD burden (Jeddi, Nabovati, and Amirazodi, 2017). Mobile technology offers a low-cost, ease-
of-access platform for chronic disease self-management (Whitehead & Seaton, 2016), 
potentially slowing disease progression and improving health outcomes (Jeddi, 2017). The 
purpose of this project was to utilize a CKD-specific mobile application, CARELogiQ, to facilitate 
symptom management; increasing patient satisfaction and decreasing hospitalizations and ER 
visits over three months. A five-database literature review yielded six high-quality articles; three 
level I, two level II, and one level III evidence based on JHNEBP (Dang & Dearholt, 2017). 
Evidence supports a multifaceted approach to effectively use a CKD-specific mobile application 
for patient and provider communications, appointment and biometric check reminders, 
education, and telemonitoring of BP and weight. The Stetler Model guided the project (Stetler, 
2001). In a Northwest Indiana nephrology clinic, CARELogiQ was used to report symptoms, 
communicate with patients and providers, and record medical appointments. DaVita’s Kidney 
Smart© educational class provided education. Participants recorded weekly BP and weights 
manually in a log. Weekly calls collected BP and weight results, reminded participants to use 
CARELogiQ to report symptoms, encouraged medication adherence, and continued 
telemonitoring. Aggregate and person-to-person hospitalization/ER visit comparisons, and a 
post-intervention satisfaction-of-care survey were completed. Healthcare utilization was less in 
the intervention group (N = 10, M = 0.00, SD = 0.00) compared to the non-intervention group (N 
= 32, M = 0.125, SD = 0.42) (t(40) = .930, p = .36) . Rate of healthcare utilization in the 
intervention group (N = 10) did not change from pre (M = 0.00, SD = 0.00) to post-intervention 
(M = 0.00, SD = 0.00). Participants were satisfied with use of CARELogiQ. CARELogiQ has the 
potential to reduce healthcare utilization by improving self-management, thus effectively 
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impacting CKD burden. Significant outcomes may be attainable for future CARELogiQ projects 
by increasing sample size, lengthening implementation time, increasing functionality of 
CARELogiQ, and providing a smart device to participants. 
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  CHAPTER 1 
INTRODUCTION 
Background 
Chronic kidney disease (CKD) is defined by the Kidney Disease Improving Global Outcomes 
(KDIGO) as any consequential kidney structure or function abnormalities persisting greater than 
three months (2012). Hypertension (HTN) and diabetes mellitus (DM) are the most common 
causes of CKD (NKF, 2017). Based on the National Kidney Foundation’s (NKF) Kidney Disease 
Outcomes Quality Initiative (KDOQI) 2002 guidelines, moderate CKD or Stage 3 CKD is 
described by a glomerular filtration rate (GFR) of 30 to 59 mL/min/1.73 m2, and severe CKD, 
Stage 4, is a GFR of 15-29 mL/min/1.73 m2 (KDOQI, 2002). The 2012 KDIGO guidelines further 
subcategorize the stages of CKD with albuminuria categories a1, a2, and a3 (KDIGO, 2012). 
While many patients do not experience symptoms until irreversible kidney damage has 
occurred, patients with CKD may experience nausea and vomiting, lack of appetite, fatigue and 
weakness, difficulty sleeping and mental impairments, muscle cramps, lower extremity swelling, 
itching, chest pain and shortness of breath, and changes in urination (Mayo Foundation for 
Medical Education and Research, 2018).  
In the United States (US), the prevalence of CKD Stages 1-5 is 15%, with CKD Stages 3-5 
at 7%, costing Medicare $79 billion for all CKD beneficiaries in 2016 (United States Renal Data 
System (USRDS, 2018). These numbers do not take into account the costs of CKD progressing 
into dialysis or kidney transplant. CKD is associated with high healthcare costs, as well as 
adversely affecting health outcomes and quality of life (Donald et al., 2018). Control of HTN and 
DM, along with correction of metabolic acidosis are part of the interventions identified to reduce 
progression of the disease (Vassalotti, Centor, Turner, Greer, Choi, Sequist, & NKF KDOQI, 
2015). Symptom management would decrease hospitalization and emergency room (ER) visits, 
thus decreasing utilization of healthcare (He et al., 2017).  
MOBILE APPLICATION IN CKD POPULATION 
 
2 
Data from the Literature Supporting Need for the Project  
Vassalotti et al. (2015) encouraged the majority of CKD patients to be cared for by primary 
care clinicians, due to the prevalence of CKD exceeding the availability of nephrologists. Other 
literature suggests that self-management of CKD could also decrease the burden of this patient 
population on the healthcare system (Jeddi, Nabovati, & Amirazodi, 2017). According to 
Whitehead and Seaton (2016), chronic disease health outcomes may improve with self-
management programs. The Institute of Medicine defines self-management as the individual’s 
responsibilities to live well with one or more chronic diseases, which is commonly used in the 
literature pertaining to self-management topics (Packer, Francini, Audulv, Alizadeh, van Gaal, 
Warner, & Kephart, 2018). Lee, Wu, Hsieh, and Tsai (2016) further echo this definition of self-
management, adding that self-management encompasses self-monitoring and symptom 
management. 
Mobile technology (mHealth) may offer a low cost, ease of access platform to implement 
self-management interventions of chronic conditions (Whitehead & Seaton, 2016). In recent 
years, healthcare has seen a boom of mobile phone applications (app) utilized not only for 
chronic disease management, but specifically CKD as well, including self-management (Jeddi et 
al., 2017). Utilizing an app to self-manage CKD along with symptom monitoring has the potential 
to slow disease progression and improve health outcomes (Jeddi et al., 2017). While poor self-
management and lack of adherence to treatment guidelines can lead to adverse clinical 
outcomes, this type of app can facilitate the patient’s self-management by easing the acquisition 
of health information and improving communication with HCPs, as well as encouraging 
compliance with blood sugar and blood pressure (BP) monitoring, supporting physical activity, 
providing nutritional guidelines, and promoting adherence to medication regimens (Jeddi et al., 
2017). 
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Data from the Clinical Agency Supporting Need for the Project 
A local nephrologist has developed an app to facilitate CKD self-management in his patient 
population. The app has the ability to record and, if necessary, access the patient’s health care 
provider (HCP) to report symptoms, as well as deliver personalized education to the patient. 
The nephrologist was interested in utilizing the app for symptom management with a goal to 
increase patient satisfaction of their care with the use of the app, while decreasing healthcare 
utilization, including hospitalizations and ER visits. Out of 264 active patients, the practice had 
180 patients with stage III to stage V CKD.  
Purpose of the Evidence-Based Practice Project 
 The purpose of this project was to evaluate the effectiveness of a mobile application 
developed by a local nephrologist to facilitate symptom management in order to increase patient 
satisfaction and to decrease hospitalizations and emergency room visits over a four-month 
period. 
PICOT Question 
 Among patients with moderate to severe CKD (P), how effective is the mobile application, 
CARELogiQ, to self-manage symptoms (I) compared to non-intervention (C) in order to reduce 
healthcare utilization and increase patient satisfaction with care (O) over a four-month period 
(T).  
Significance of the EBP Project 
 Implications of this project were to initiate the use of an app developed by a local 
nephrologist in an outpatient CKD clinic to positively affect CKD self-management resulting in 
increased patient satisfaction of care and decreased hospitalizations and ER visits. Self-
management in this CKD population has the potential to improve healthcare outcomes, as well 
as decrease costs associated with hospitalization and ER visits. 
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CHAPTER 2 
EBP MODEL AND REVIEW OF LITERATURE 
 In this chapter, the process of this EBP project will be expanded upon with the guidance 
of the Stetler model of evidenced-based practice. “Johns Hopkins Nursing Evidence-Based 
Practice Research Evidence Appraisal Tool” (JHNEBP) is utilized to appraise the level and 
quality of evidence used to develop best practice recommendations in order to guide the 
practice change.  
Evidence-based Practice Model 
Overview of EBP Model 
 The Stetler model of evidenced-based practice is a step-by-step approach to use 
research evidence in developing nursing practice (Stetler, 2001). Research can be used 
instrumentally, conceptually, or symbolically, in an informal or formal way, directly or indirectly, 
at the level of the individual, group, or organization (Schmidt & Brown, 2019). According to 
Stetler (2001), the use of knowledge is influenced not only by a user’s internal characteristics, 
but also by external environmental factors. This model consists of five phases: Preparation, 
Validation, Comparative Evaluation/Decision Making, Translation/Application, and Evaluation 
(Stetler, 2001). The model was selected to guide this project due to the applicability to an 
individual practitioner with an increased level of knowledge and skill, which facilitated decision 
making to translate research findings into practice (Stetler, 2001). This model guided the 
process of participants using a mobile application to self-manage symptoms associated with 
CKD.  
Application of EBP Model to DNP Project 
 Phase I: Preparation. The first step in the Stetler model is identifying the problem. The 
problem for this EBP project is CKD being associated with high healthcare costs, as well as 
adversely affecting health outcomes and quality of life (Donald et al., 2018). The catalyst for this 
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specific project was an innovative program goal. A local nephrologist developed a mobile app 
and requested a project leader to guide operationalizing this intervention. The interest of the 
nephrologist in launching a newly developed app is an influencing factor. The project leader 
seeks to know if employment of a mobile application to manage symptoms decreases 
unscheduled healthcare utilization. The literature was reviewed based on a clinical question and 
a PICOT question was developed. A search strategy was prepared as shown in Table 2.1. The 
highest levels of evidence were sought to guide this project.  
Phase II: Validation. The second step in the Stetler model is validation (Stetler, 2001). 
The literature was searched for relevant articles pertaining to the use of a mobile app to 
promote self-management of chronic diseases, including CKD. The selected articles were 
evaluated and appraised with the JHNEBP tool for level and quality. An evidence table was 
created, as shown in Table 2.2, including the level and quality of each piece of evidence. The 
project leader decided to continue the EBP process due to the selected evidence determined to 
be fit for use. 
Phase III: Comparative evaluation/Decision Making. In the comparative evaluation 
and decision-making phase, synthesis of the evidence and evaluation of commonalities to be 
used in project was completed, leading to best practice recommendations. The project leader 
decided to use these findings to change practice by using the CARELogiQ app to aid 
participants in self-management of CKD. 
Phase IV: Translation/Application. A plan of change to implement the CARELogiQ 
app was formulated and was acted upon. Participants downloaded the mobile app and utilized 
the platform as previously described.  
Phase V: Evaluation. In this phase, the project leader evaluated the outcome data to 
determine if the practice change of implementing the CARELogiQ app to facilitate symptom 
management met the outcome goals of increasing patient satisfaction and reducing healthcare 
utilization over a four-month period. Formal evaluation (formative and summative) of the 
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implementation of a mobile app to manage symptoms to decrease unscheduled healthcare 
utilization was conducted in this stage. 
Strengths and Limitations of EBP Model for DNP Project 
 Strengths of the Stetler model include the ability to integrate research into practice either 
informally or formally, at an individual level or up to an organizational level, incorporating 
evidence into daily practice. Since the project leader was working mostly on her own, this model 
worked to guide the EBP project. The model also accommodated for collaboration with staff 
during retrieval of patient information. 
 A limitation of the Stetler model is the need for a project leader to be competent, having 
sufficient knowledge and skill of EBP practice to successfully use this EBP model. 
Literature Search 
Sources Examined for Relevant Evidence 
An exhaustive search of the following databases was completed (see Table 2.1): 
Cumulative Index of Nursing and Allied Health Literature (CINAHL), Cochrane Library, Johana 
Briggs Institute (JBI), Medline with full text via EBSCO (Medline), ProQuest Nursing and Allied 
Health Literature (ProQuest). Keywords searched within CINAHL, Medline, and ProQuest with 
Boolean operators were (“chronic kidney disease*” OR “chronic disease*”) AND (mHealth OR 
m-health OR “mobile app*” OR “mobile health” OR smartphone* OR “cell* phone*”) AND (“self 
manag*” OR “self care”). Cochrane Library was searched with the MeSH heading (MM mobile 
applications). JBI was searched with (chronic kidney disease OR chronic disease AND mHealth 
OR m-health OR mobile application OR mobile health OR smartphone OR cellphone) with a 
five-year limiter. While CKD was the focus of this EBP project, due to the limited results specific 
to CKD, the search was expanded to chronic diseases as well. A Prisma flow diagram (see 
Figure 2.1) details the search process. 
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Table 2.1 
Literature Search Results 
Database Keyword(s) Limiters Date 
Restraints 
Results Relevance/Saved 
CINHAL 
 
 
 
 
 
 
 
 
 
 
 
Cochrane 
Library 
 
 
 
 
Johana 
Briggs 
Institute 
 
 
 
 
 
 
Medline 
with Full 
text via 
EBSCO 
 
 
 
 
 
 
 
ProQuest 
Nursing and 
(“chronic kidney 
disease*” OR 
“chronic disease*”) 
AND (mHealth OR 
m-health OR “mobile 
app*” OR “mobile 
health” OR 
smartphone* OR 
“cell* phone*”) AND 
(“self manag*” OR 
“self care”) 
 
 
(MM mobile 
applications) 
 
 
 
 
(“chronic kidney 
disease*” OR 
“chronic disease*”) 
AND (mHealth OR 
m-health OR “mobile 
app*” OR “mobile 
health”) 
 
 
(“chronic kidney 
disease*” OR 
“chronic disease*”) 
AND (mHealth OR 
m-health OR “mobile 
app*” OR “mobile 
health” OR 
smartphone* OR 
“cell* phone*”) AND 
(“self manag*” OR 
“self care”) 
 
English 
Peer 
Reviewed 
 
 
 
 
 
 
 
 
 
English 
Peer 
Reviewed 
 
 
 
English 
Peer 
Reviewed 
 
 
 
 
 
 
English 
Peer 
Reviewed 
 
 
 
 
 
 
 
 
English 
June 2014- 
June 2019 
 
 
 
 
 
 
 
 
 
 
June 2014- 
June 2019 
 
 
 
 
June 2014- 
June 2019 
 
 
 
 
 
 
 
June 2014- 
June 2019 
 
 
 
 
 
 
 
 
 
June 2014- 
June 2019 
74 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
25 
 
 
 
 
 
 
 
 
252 
 
 
 
 
 
 
 
 
 
 
541 
2 Systematic 
Reviews 
 
 
 
 
 
 
 
 
 
 
0 
 
 
 
 
 
0 
 
 
 
 
 
 
 
 
3 (2 Systematic 
Reviews, 1 
Overview of 
Systematic 
Reviews, 2 
duplicates from 
CINAHL) 
 
 
 
 
0 (2 duplicates in 
Medline) 
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Allied 
Health 
Database 
 
 
 
 
 
 
 
 
Hand 
Search 
(JMIR 
2018) 
(“chronic kidney 
disease*” OR 
“chronic disease*”) 
AND (mHealth OR 
m-health OR “mobile 
app*” OR “mobile 
health” OR 
smartphone* OR 
“cell* phone*”) AND 
(“self manag*” OR 
“self care”) 
 
Peer 
Reviewed 
 
 
 
 
 
 
 
 
 
English 
Peer 
Reviewed 
 
 
 
 
 
 
 
 
 
 
 
 
June 2014- 
June 2019 
 
 
 
 
 
 
 
 
 
 
 
1 Systematic 
Review of 
Systematic 
Reviews 
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Figure 2.1 
 
Prisma Flow Diagram 
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Levels of Evidence  
 Level of evidence for this EBP project was assessed by using the JHNEBP, which 
categorizes evidence based on the level of study design (Dang & Dearholt, 2017). Dang and 
Dearholt (2017) presume that the higher the level and quality of the evidence, the stronger the 
recommendation represents best practice. Answering three simple questions determines the 
level of evidence, ranging from I to III (Dang & Dearholt, 2017). 
 Level I evidence incorporates the following study types: experimental studies, 
randomized controlled trials (RCTs), explanatory mixed methods with only level I quantitative 
studies, or systematic reviews of RCTs, with or without meta-analysis (Dang & Dearholt, 2017). 
Dang and Dearholt (2017) categorize level II evidence as quasi-experimental studies, 
explanatory mixed methods with only level II quantitative studies, or systematic reviews 
consisting of RCTs and/or quasi-experimental studies, with or without meta-analysis. Level III 
evidence is comprised of quantitative nonexperimental studies; explanatory mixed methods with 
only level III quantitative studies; exploratory, convergent, or multiphasic mixed methods 
studies; systematic reviews of a combination of RCTs, quasi-experimental, and/or 
nonexperimental studies; or qualitative studies or systematic reviews of qualitative studies, with 
or without meta-analysis (Dang & Dearholt, 2017). 
 The evidence used in this EBP project were all systematic reviews ranging from level I 
(three pieces of evidence utilizing all RCTs) to level II (three pieces of evidence utilizing a 
combination of RCTs and non-RCTs) (see Table 2.2). 
Appraisal of Relevant Evidence 
JHNEBP also facilitates appraisal of quality of evidence by utilizing a straightforward 12-
item checklist to appraise the quality of systematic reviews, ranging from High to Low (Dang & 
Dearholt, 2017). High quality evidence is consistent with generalizable results; sufficient sample 
sizes for study design; and provides adequate control, definite conclusions, and consistent 
recommendations which is based on a comprehensive, scientific literature review (Dang & 
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Dearholt, 2017). Good quality differs from high quality in that results are reasonably consistent, 
with some control; conclusions are fairly definitive; and recommendations are reasonably 
consistent, based on fairly comprehensive literature that includes some scientific evidence 
(Dang & Dearholt, 2017). Grades of Low quality or Major flaw encompass little evidence with 
inconsistent results, insufficient sample size for the study design, and inability to draw 
conclusions (Dang & Dearholt, 2017). All six of the systematic reviews used in this EBP project 
were of high quality, based on JHNEBP, although many of the studies used in the reviews were 
of moderate to low quality, due to small sample sizes. 
Level I evidence. Jeddi et al. (2017) produced a systematic review of eight RCTs 
evaluating the efficacy of IT-based interventions on self-management clinical outcomes (BP, 
interdialytic weight gain, intact parathyroid hormone, and ultrafiltration rate) and process of care 
outcomes (medication adherence, patient knowledge, medication dose/usage, BP, and sodium 
intake) in CKD patients. The interventional classifications consisted of use of 
smartphone/personal digital assistant devices (PDAs) (software/application/short message 
service (SMS)) to transfer data to HCP/researchers, use of wearable devices to record BP and 
weight, computerized systems for data transfer to and from patients through the internet, or a 
combination of all three. The duration of the studies lasted from three weeks to 12 months. The 
smartphone/PDA functionalities were categorized by inform, record, display, communicate, 
remind/alert, and guide. The results showed statistically significant outcomes in 80% of the 
studies, with 75% being clinical outcomes and 86% process of care outcomes. Quality was 
assessed as high, based on the results (consistent, generalizable), sample size (sufficient), 
control (adequate), conclusions (definite), and recommendations (consistent/based on scientific 
evidence). 
 Lee, Choi, Lee, and Jiang (2018) completed a systematic review of 12 RCTs to examine 
the effectiveness of mHealth interventions on chronic disease management health outcomes 
and process measures. MHealth interventions utilized smartphones as a mobile device, tablets, 
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or telemonitoring wireless devices with components of remote symptom monitoring/self-
assessment, automatic messages, and education. Duration of studies ranged from two to 12 
months. Health outcomes were measurements of physical functioning (gait/balance, fatigue, 
etc.), psychological functioning (quality of life, depression, and anxiety), medication adherence, 
and/or ease of symptom evaluation and reporting to HCPs. Process measures included patient 
satisfaction and interventional feasibility. Incorporating mobile applications in chronic disease 
management showed a statistically significant effect on outcomes of interest in 83.3% of the 
studies. The authors concluded that automated text reminders, frequent and accurate symptom 
monitoring, and improved communication between patients and HCPs result in improved 
chronic condition self-management. Quality was assessed as high, based on the results 
(consistent, generalizable), sample size (sufficient), control (adequate), conclusions (definite), 
and recommendations (consistent/based on scientific evidence). 
 Whitehead and Seaton (2016) conducted a systematic review of nine RCTs assessing 
the efficacy of symptom self-management utilizing mobile phone and tablet apps on disease 
specific outcomes, which included blood glucose (BG), asthma symptoms, medication use, 
peak flows, BP, weight, and pedometer counts. Interventions included the use of a disease 
specific app with or without automatic feedback, either alone or in combination with clinician 
input or support (either by text or phone call). Chronic diseases of patients in this study included 
DM, chronic lung disease, and cardiovascular disease (CVD). The duration or ranged from three 
months to one year. Statistically significant effects were shown in 66.6% of studies on disease 
specific outcomes and some combination of app usage. App only interventions were statistically 
significant in improvement of symptom management in 60% of the studies. Quality was 
assessed as high, based on the results (consistent, generalizable), sample size (sufficient), 
control (adequate), conclusions (definite), and recommendations (consistent/based on scientific 
evidence). 
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 Level II evidence. A systematic review of systematic reviews by Kitsiou, Pare, Jaana, 
and Gerber (2017) evaluated the efficacy of mHealth interventions of remote patient monitoring 
and clinical feedback delivery for DM self-management (encouragement, education, reminders, 
and recommendations) on glycemic control in diabetic patients. This review examined 15 
systematic reviews, seven of which were comprised of RCTs only and the remaining were 
comprised of RCTs, non-RCTs, and cohort studies with pre-post design. MHealth interventions 
included SMS, mobile applications, Blue-tooth enabled glucometers, and data entry/patient 
support through cellphone accessible websites/web-portals. Duration of studies were from two 
weeks to 12 months, with most study durations being three to 12 months. The one measurable 
outcome was glycemic control defined by HgA1c. There was no effect found from text 
messaging alone. Nonstatistical positive effect was found with combination of SMS and internet 
app for transmission of BG, reinforcement of diet/exercise, education and medication 
adjustment. Text messaging combined with clinical feedback had a statically significant effect on 
glycemic control. Addition of an education component increased the effect size. Quality was 
assessed as high, based on the results (consistent, generalizable), sample size (sufficient), 
control (adequate), conclusions (definite), and recommendations (consistent/based on scientific 
evidence). 
 A systematic review of 23 systematic reviews of RCTs and non-RCTs by Marcolino et al. 
(2018) evaluated the effects of mHealth interventions on chronic and noncommunicable 
diseases, such as asthma, cardiac disease, congestive heart failure, chronic lung disease, 
cancer, and DM. The most frequent interventions included SMS for reminders, education, 
motivation, or prevention. Duration of interventions lasted from a few minutes to 24 months. 
Primary outcomes were divided into clinical outcomes (frequency of hypoglycemic events, 
symptoms, or death), surrogate outcomes (HgA1c, BP, lipid profile, CVD risk profile, lung 
function, neb use, weight, BMI, behavioral or lifestyle changes), and process of care outcomes 
(attendance rates, medication compliance, data management,  communication, time to dx, time 
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to treat, or professional workload changes). Secondary outcomes were cost, patient satisfaction, 
and potential harms and adverse effects. Regarding clinical outcomes, mHealth interventions 
improved symptoms in asthma (text messaging), chronic obstructive pulmonary disease (SMS 
program), and heart failure (mobile technology counseling).  
There were no statistically significant improvements in chemotherapy symptoms (mobile 
app symptom report with recommended self-care advice) (Marcolino et al., 2018). MHealth 
interventions resulting in surrogate outcomes showed improved peak flow scores in asthma, 
reduced mortality and hospitalizations, improved QOL, improved glycemic control, and improved 
BP. SMS reminders improved process of care outcomes as evidenced by attendance rates, 
reduced costs, and improved adherence to TB and HIV therapy resulting in decrease viral load. 
Secondary outcomes were also improved by mHealth interventions, as evidenced by effective 
data collection and reporting, reduction of face to face communication, reduction in 
communication delays, improved patient-provider communication, and statistically significant 
provider to provider communication. Quality was assessed as high, based on the results 
(consistent, generalizable), sample size (sufficient), control (adequate), conclusions (definite), 
and recommendations (consistent/based on scientific evidence). 
 Level III evidence. Alessa, Abdi, Hawley, and de Witt (2018) completed a systematic 
review. The purpose of the study was to assess the efficacy of an app to lower BP in individuals 
with one or more of the following: HTN, metabolic syndrome risk factors, obstructive sleep 
apnea with high cardiovascular risk, and overweight, while also assessing the usability of the 
app and patient satisfaction with the use. This systematic review synthesized 21 (nine RCTs, 10 
quasi experimental studies and two qualitative studies). While the inclusion of the two qualitative 
studies lowered the evidence level to III, those two articles specifically focused solely on the 
usability and user satisfaction component of the systematic review. This source of evidence was 
included due to the remaining 19 studies focused on the efficacy of the app related to BP to be 
of level II evidence (RCTs and quasi-experimental studies). The interventions in this review 
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were a mobile phone or tablet app that collected data, provided feedback, connected 
with/informed HCP in order to self-manage (measure BP/other biometrics, healthy diet, physical 
activity, weight management, medication adherence, and stress management/coping) to HTN. 
The app functions were categorized into seven main functions: self-monitor, goal setting, 
remind/alert, automatic feedback, education, HCP communication, and stress management. 
Duration of the studies ranged from one to 12 months. Study outcomes were BP measurements 
and mobile app usability, attitudes, and satisfaction. Alessa et al. (2018) concluded that 67% of 
the studies showed a significant association between app use and decreased BP, although 
evidence was inconclusive regarding which combination of functionality of the app was most 
effective. The app was highly acceptable and easy to use, and participants were satisfied with 
use of the app. Quality was assessed as high, based on the results (consistent, generalizable), 
sample size (sufficient), control (adequate), conclusions (definite), and recommendations 
(consistent/based on scientific evidence). 
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Table 2.2 
 
Evidence Table 
 
Citation 
(APA) 
Purpose Design 
 
Sample Measurement/ 
Outcomes  
 
Results/ 
Findings 
Level/ 
Quality  
Alessa, T., 
Abdi, S., 
Hawley, 
M.S., de 
Witte, L. 
(2018). 
To assess the 
effectiveness 
of using apps 
to lower blood 
pressure, and 
to assess 
usability and 
patients’ 
satisfaction 
with app usage 
 
 
 
 
Systematic 
review with 
RCTs and 
quasi 
experimental 
studies 
21 studies (9 
RCTs, 10 
quasi 
experimental 
studies, and 2 
qualitative 
studies 
 
n = 3112 with 
a mean age of 
42.4 to 69.5 
years having 
hypertension, 
metabolic 
syndrome risk 
factors, 
obstructive 
sleep apnea 
with high 
cardiovascular 
risk, and/or 
overweight 
 
 
 
 
 
 
 
Effectiveness of apps 
in lowering blood 
pressure 
 
Effectiveness of apps 
in app usability 
 
Effectiveness of apps 
in patients’ 
satisfaction of use  
 
 
There was a significant 
association (p < .05) between 
use of apps and decreased 
blood pressure in 67% of the 
studies.  
 
The app was highly accepted in 
all 9 studies. 
 
Participants were satisfied with 
the apps, accepted using them 
and found them easy to use. 
 
 
Level III 
 
 
Quality 
High 
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Jeddi, F.R., 
Nabovati, 
E., 
Amirazodi, 
S. (2017). 
 
To assess the 
features and 
effects of 
automated IT-
based 
interventions 
on the 
outcomes of 
self-
management 
in CKD 
patients 
  
Systematic 
review of 
RCTs 
8 RCTs 
 
n = 1637 
including 
Hispanic 
transplant 
candidates and 
their family and 
friends, 
hemodialysis 
patients, adults 
with CKD or 
diabetes, 
including 
veterans, with 
uncontrolled 
blood pressure 
Effectiveness of the 
IT intervention on 
clinical outcomes 
(BP, IDWGA, iPTH 
and ultrafiltration 
rate) 
 
Effectiveness of the 
IT intervention on 
process of care 
outcomes 
(medication 
adherence, patients’ 
knowledge, 
medication dose, 
medication usage, 
BP reading, and 
dietary sodium 
intake) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Self-management outcomes 
statistically significant (p < 
.0001 to .05) in 80% of the 
studies (75% of the clinical 
outcomes and 86% of the 
process of care outcomes). 
 
Level I 
 
Quality 
High 
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Kitsiou S., 
Pare, G., 
Jaana, M., 
& Gerber, 
B. (2017). 
To 
systematically 
pool evidence 
on the 
effectiveness 
of mHealth 
interventions in 
patients with 
diabetes 
Systematic 
review of 
systematic 
reviews 
containing 
RCTs, non-
RCTs, and 
cohort 
studies 
 
 
15 systematic 
reviews (7 
RCTs only, 8 
with RCTs, 
non-RCTs, and 
cohort studies 
with pre-post 
design) 
 
n = 11,833 
patients with 
diabetes 
Effectiveness of 
mHealth 
interventions (text 
messaging of 
encouragement, 
education, reminders, 
and 
recommendations, 
mobile apps, Blue-
tooth enabled 
glucometers, 
websites/portals for 
data entry and 
patient reports) on 
HbA1c 
 
No effect on HgA1c from text 
messaging alone [MD -0.15% 
(95% CI: -0.77, 0.47)]. 
 
Positive, insignificant effect 
[0.3% (CI: 0.0, -0.5%)] of 
combined SMS with Internet 
app for transmission of BG, 
reinforcement of diet and 
exercise, education, and 
medication adjustment. 
 
Text messaging and clinical 
feedback have a beneficial 
effect on glycemic control [MD 
of -0.05% (95% CI: -0.74, -
0.26), 3 trials, 280 patients]. 
Addition of education 
component increased effect 
size (MD -0.85% vs -0.43). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level II 
 
Quality 
High 
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Lee, J., 
Choi, M., 
Lee, S.A., 
& Jiang, N. 
(2018). 
To examine 
the 
effectiveness 
of mHealth 
interventions 
on health 
outcomes and 
process 
measures of 
chronic 
diseases 
Systematic 
review of 
RCTs 
12 RCTs 
 
n = 3469 
including adult 
patients with 
lung, breast, or 
colorectal 
cancer on 
chemotherapy; 
fibromyalgia; 
heart failure; 
allergic rhinitis 
and asthma; 
spina bifida; 
cardiovascular 
disease; 
Parkinson’s 
disease; and 
lung 
transplants  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effectiveness of the 
mHealth 
interventions on 
health outcomes 
(physiological 
=gait/balance, 
fatigue, 
nausea/vomiting/diarr
hea, sore 
mouth/throat, hand-
foot syndrome, and 
pain) and 
(psychological = 
QOL, depressive 
symptoms, anxiety) 
and process 
measures 
(participants’ 
adherence to, 
satisfaction with, 
and/or the level of 
engagement with 
mHealth systems) 
Of the articles, 83.3% showed 
statistically significant effect (p 
= .001 to .05) on health 
outcomes by incorporating 
mobile apps in managing 
chronic dx (improved physical 
functioning, adherence to 
prescribed meds, and/or ease 
of symptom evaluation and 
reports to care providers), and 
process measures (patient 
satisfaction with mHealth 
management and ease of use 
of smartphone based self-
management interventions). 
Level I 
 
Quality 
High 
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Marcolino, 
M.S., 
Oliverira, 
J.A.Q., 
D’Agostino, 
M., Ribiero, 
A.L., 
Alkmim, 
M.B.M., & 
Novillo-
Ortiz, D. 
(2018). 
To assess the 
effectiveness 
of mHealth 
interventions 
on chronic and 
non-
communicable 
disease 
Systematic 
review of 
systematic 
reviews 
containing 
RCTs and 
non-RCTs 
23 systematic 
reviews 
 
n = 79,665 
Primary outcomes: -
clinical (frequency of 
hypoglycemic events, 
symptoms, death) 
-surrogate (HgA1c, 
BP, lipid profile, CVD 
risk profile, lung 
function, neb use, 
weight, BMI, 
behavioral or lifestyle 
changes) 
-process of care 
(attendance rates, 
medication 
compliance, data 
management, 
communication, time 
to dx, time to treat, 
professional 
workload changes) 
Secondary 
outcomes: cost, 
patient satisfaction 
and potential harms 
and adverse effects 
mHeath interventions improved 
symptoms in asthma (text 
messaging) [MD 0.36, (95% CI: 
-0.56, -0.17)], and HF (mobile 
technology counseling) (RR 
reduction 20%). No statistically 
significant improvement in 
COPD (SMS program) or 
chemotherapy symptoms 
(mobile app symptom report 
with recommended self-care 
advice). 
 
Improved peak flow scores in 
asthma [MD -11.12, CI: 95%, -
19.56, -2.68)], reduced 
mortality and hospitalizations, 
improved QOL, glycemic 
control, and BP. 
 
SMS reminders improved 
attendance rates, reduced 
costs, and improved adherence 
to TB and HIV therapy resulting 
in decrease viral load. 
 
Effective data collection and 
reporting, reduction of face to 
face communication, reduction 
in communication delays, 
improved patient-provider 
communication, statistically 
significant provider to provider 
communication. 
*not all statistics given in article 
Level II 
 
Quality 
High 
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Whitehead, 
L., & 
Seaton, P. 
(2016). 
To assess the 
effectiveness 
of mobile 
phone and 
tablet apps in 
self-
management 
of key 
symptoms of 
long-term 
conditions 
Systematic 
review 
containing 
RCTs 
9 RCTs 
n = 2278 
patients aged 
33.8 to 72.1 
years with 
diabetes, 
chronic lung 
disease, and 
cardiovascular 
disease 
Effectiveness of 
mobile phone and 
tablet app on disease 
specific outcomes 
(DM, chronic lung 
disease, and CVD) 
Of the articles, 66.6% of 
interventions showed 
statistically significant effects 
on disease specific outcomes 
of interest. 60% app only 
interventions statistically 
significant in improvement of 
symptom management. 
*statistics of individual RCTs 
not given in article. 
Level I 
 
Quality 
High 
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Construction of Evidence-based Practice 
Synthesis of Critically Appraised Literature 
Synthesis of the preceding literature identified mHealth interventions to improve 
outcomes in chronic disease, which may be translational to a CKD population due to similar 
needs of this chronic disease population. Common themes to improve disease-specific 
outcomes include communication, reminders, telemonitoring, and education (Alessa et al., 
2018, Jeddi et al., 2017, Kitsiou et al., 2017, Lee et al., 2018, Marcolino et al., 2018, and 
Whitehead & Seaton, 2016). Use of these common themes can translate into best practice for 
implementation of a mobile app to manage symptoms in patients with CKD. 
Communication. In all six appraised sources of evidence, mHealth utilized 
communication to improve measured outcomes (Alessa et al., 2018, Jeddi et al., 2017, Kitsiou 
et al., 2017, Lee et al., 2018, Marcolino et al., 2018, and Whitehead & Seaton, 2016). 
Communication between patient and HCP, as well as communication between HCPs is a 
valuable intervention. Communications in the reviewed literature were either sent to the patients 
by being generated by a HCP or were sent as a result of the app’s automated responses 
(Alessa et al., 2018, Jeddi et al., 2017, Kitsiou et al., 2017, Lee et al., 2018, Marcolino et al., 
2018, and Whitehead & Seaton, 2016). 
Reminders. Another function that seems to be a commonality between four of the six 
sources of evidence is the use of reminders (Alessa et al., 2018, Jeddi et al., 2017, Kitsiou et 
al., 2017, and Marcolino et al., 2018). Reminders addressed appointment times as well as 
medication times and disease-specific biometric evaluations, such as BP checks. 
Telemonitoring. Telemonitoring or the wearing of a device to record and/or transmit 
biometric readings, such as BP, weight, gait, BG, and peak flows, was also demonstrated to 
improve disease-specific outcomes in five of six articles (Alessa et al., 2018, Jeddi et al., 2017, 
Kitsiou et al., 2017, Lee et al., 2018, and Marcolino et al., 2018).  
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Education. Five of six articles demonstrated disease-specific education as an integral 
part of a mHealth intervention (Alessa et al., 2018, Jeddi et al., 2017, Kitsiou et al., 2017, Lee et 
al., 2018, and Marcolino et al., 2018). Media used for education included SMS, internet, email 
and videos. 
Best Practice Model Recommendation 
After reviewing the appraised literature, the identified best practice to address 
implementation of a mobile app to manage symptoms in patients with CKD incorporates 
communication, reminders, telemonitoring, and education (see Figure 2.2). By integrating these 
components into practice, reduced healthcare utilization and increased patient satisfaction was 
expected. 
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Figure 2.2 
 
Practice Change 
 
 
  
Identify eligible participants from 
nephrologist’s daily schedule 
 
Nephrologist to introduce project leader 
to participant at completion of his office 
visit 
 
Participants given handout of 
details of EBP project 
 
After consenting, 
participants aided in 
downloading CARELogiQ 
 
Participants instructed to 
record blood pressures and 
weights weekly, record all 
appointments in the app, and 
complete the Kidney Smart© 
education program 
 
Project leader to make weekly calls to 
participants to remind them to continue to 
record weekly blood pressures and 
weights, to enter upcoming clinic 
appointments in the app, to adhere to their 
medication regimen, and to report any 
symptoms in the app 
 
Complete patient satisfaction 
survey at conclusion of project 
MOBILE APPLICATION IN CKD POPULATION 
 
26 
CHAPTER 3 
IMPLEMENTATION OF PRACTICE CHANGE  
The CARELogiQ platform was the cornerstone of this practice change. Eligible 
participants downloaded the CARELogiQ app to begin the process of self-management. 
Practice change was implemented by utilizing the synthesized best practice interventions 
explained above. 
Participants and Setting 
 Participants taking part in this practice change were patients of a local nephrologist, with 
CKD, between stages III and V, not on dialysis. The project site was an outpatient nephrology 
practice in a Midwest town, consisting of nine nephrologists and seven office locations. Only 
patients of the nephrologist who developed the mobile application were included to participate. 
Only one of this nephrologist’s two offices was the initial target site of the EBP project. Due to a 
low number of participants, a second office site was added. 
Complete inclusion criteria for this EBP project required participants: 
• 18 years or older 
• English speaking 
• CKD III to V (including post transplant) 
• Consent to participate in the project 
• Have a smartphone capable of installing this application 
• Agree to download and use the application 
• Able to navigate the application 
Potential participants were excluded from participating in the project based on the following 
criteria: 
• Currently receiving dialysis 
• Pregnancy 
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Pre-Intervention Group Characteristics 
 The targeted nephrology practice was comprised of 264 adult patients, with 180 of these 
patients diagnosed with CKD III to IV. Of those 180 patients, 146 had stage III CKD, 27 had 
stage IV CKD, two had stage V CKD, and five were stage V post transplantation. Patients with 
CKD III made up 55.3% of the total population and 81.11% of the moderate to severe CKD 
population, while CKD IV was 10.22% and 15%, CKD V was 0.75% and 1.11%, and CKD V 
post transplantation was 1.89% and 2.77%. Eighty-five (47%) of the 180 patients were male, 
and 95 (53%) were female. Within this group, race/ethnicity for 37 (21%) were “not available”, 
three (2%) were “not available/not Hispanic”, 94 (52%) were “white/not Hispanic”, four (2%) 
were “white/Hispanic”, 36 (20%) were “black or African American (AA)/not Hispanic”, one (1%) 
was “black or AA/not available”, two (1%) were “Asian/not Hispanic”, and one (1%) was 
“other/not Hispanic”. Patients were considered to be part of the practice if they have been seen 
in the office within the past year.  
 This EBP project targeted as many participants as possible from the nephrology group 
who met the stated project inclusion criteria. Comparison data consisting of CKD stage, BP, 
weight, and hospitalizations and/or ER visits was collected from the previous year’s visits, as 
well as the current visit. 
Intervention 
 To prepare for this EBP intervention, a plan was developed to provide step-by-step 
guidance for the project leader and the staff at the facility. First, eligible potential participants 
were identified from the nephrologist’s daily patient schedule. At the conclusion of the office 
visit, the nephrologist introduced the patients to the project leader. After an introduction of the 
EBP project, potential participants decided whether to join the project. Once participants 
consented to join the project, the project leader gave participants a handout of instructions on 
how to download and use the mobile application. Participants had the opportunity to download 
the mobile application with the project leader while in the office. Participants also were given 
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instructions on recording weekly home BP and weight measurements, as well as instructions for 
the educational resource, DaVita’s Kidney Smart© educational website. 
 Initiation of the intervention began with participants recording weekly home BPs and 
weights. Weekly calls to participants were made by the project leader to remind the participants 
to continue home BP and weight recordings, to collect a weekly home BP and weight, to 
encourage entering upcoming clinic appointments into the mobile application, to encourage 
adherence to medications, and to promote the use of the mobile application to report symptoms 
as any arose. Participants with abnormal BPs or weights were encouraged to follow up with 
their treating provider. The duration of the intervention was planned for 12 weeks. Participants 
continued enrollment through October 2019. At the conclusion of intervention, participants were 
given a participant satisfaction survey to assess their satisfaction with utilizing the mobile 
application. 
Comparison  
 Collection of pre-intervention data was necessary to serve as a comparison to post-
intervention data in order to analyze the efficacy of the project. Once a participant was initiated 
into the project, the project leader reviewed that participant’s chart for healthcare use, consisting 
of unscheduled hospitalizations or ER visits for the previous year, as well as for office visits 
other than scheduled follow-up appointments within the previous year. The project leader also 
reviewed the participant’s chart in order to collect data of the BP readings, last weight, and the 
stage of CKD over the past one year of office visits. 
 Data collection of a non-intervention comparison group was completed. Thirty-two 
randomly selected patient charts were reviewed, with 25 stage III CKD, five stage IV CKD, one 
stage V CKD, and one stage V CKD post transplantation to create a randomize stratified sample 
based on the total number of active patient files in the office. The ages of patients ranged from 
43 years to 92 years. Only one had a hospitalization in the past year. Three had ER visits. 
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Unplanned office visits were difficult to track, due to no specific documentation signifying the 
visit to be unplanned. 
Outcomes 
 Primary and secondary outcomes were employed to evaluate the effectiveness of the 
EBP project. The primary outcome of this EBP project was the compared number of 
unscheduled hospitalizations or ER visits from the pre-intervention and intervention groups. 
Additionally, the total number of encounters post-intervention were compared to the participant’s 
pre-intervention visits within the past year, by utilizing a paired t test. The secondary outcome 
was participant user satisfaction with the mobile application at the conclusion of the intervention. 
Participant user satisfaction was scored utilizing a Likert scale and means were compared. In 
addition to collection of the number of unscheduled hospitalizations or ER visits, the number of 
contacts with the provider or office through phone calls, mobile app usage for imputing 
symptoms, and office visits were also collected. BP and weights were analyzed by trending.  
Time  
 In collaboration with the project site facilitator, the projected timeline of this EBP project 
was determined by the literature review, constraints of the project leader’s allowable time, as 
well as the project site facilitator request. The duration of intervention in the reviewed literature 
most frequently lasted three to six months (Alessa et al., 2018, Jeddi et al., 2017, Kitsiou et al., 
2017, Lee et al., 2018, Marcolino et al., 2018, and Whitehead & Seaton, 2016). Implementation 
for this EBP project began September 1st, after IRB approval. The project strived to continue to 
invite participants to join until a number of 50 participants was reached, but due to time 
constraints, participant invitation closed October 30th.  The project duration was planned to last 
four months. 
Protection of Human Subjects 
 The project leader completed an ethics training program as evidenced by a CITI 
certificate. Approval for the EBP project was obtained from the Valparaiso University 
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Institutional Review Board. Confidential participant information was kept locked at the clinical 
site. Participants’ data were de-identified by using codes. A separate master list was used to 
assign code numbers based on chart name and date of birth. The master list identifying 
participants was kept in a separate file at the project site.  
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CHAPTER 4 
FINDINGS 
This EBP project began by asking the question: how effective is CARELogiQ to self-
manage symptoms compared to non-intervention, in order to reduce healthcare utilization and 
to increase patient satisfaction over a 12-week period. The purpose of this EBP project was to 
evaluate the efficacy of a CKD mobile application, developed by a local nephrologist, to facilitate 
symptom management, while increasing patient satisfaction, and decreasing unplanned 
hospitalizations and ER visits. In order to evaluate the effectiveness of this mobile application, 
two groups were selected from 180 patients with moderate to severe CKD, a non-intervention 
group and an intervention group. Unplanned hospitalizations and ER visits related to CKD 
symptoms were assessed within both groups. Unplanned healthcare utilization was compared 
within the intervention group pre- and post-intervention, as well as between the non-intervention 
and intervention groups. The secondary outcome of patient satisfaction was evaluated by a 
“Satisfaction of Care” survey developed by the project manager. Nine out of 10 participants 
completed the survey, but not all questions were applicable to all participants. This 12-question 
survey was administered by a phone call to participants after completion of the 12-week project. 
Other project outcomes were evaluated by analysis of weekly BP and weight recordings. 
Utilization of SPSS, version 25.0, facilitated analysis of participant demographic data, as well as 
primary and secondary outcome data. 
Participants 
In this chapter, participant characteristics are detailed and evaluated (see Table 4.1). A 
comparison group of 32 non-intervention participants was obtained from a stratified random 
sample of the above active patients, ranging in age from 43 to 92 years (M = 71.53, SD = 10.67) 
was randomly selected to reflect the total percentages in the moderate to severe CKD office 
population. Twenty-five stage III CKD, five stage IV, one stage V, and one stage V with 
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transplantation were randomly selected (see Figure 4.1). Of this group, 17 (53%) were male, 
and 15 (47%) were female (see Figure 4.2). Race/ethnicity for three (9.4%) was “not available”, 
18 (56.3%) were “white/not Hispanic”, 9 (28.1%) were “black or AA/not Hispanic, 1 (3.1%) was 
“black or AA/not available”, and one (3.1%) was “other/not Hispanic” (see Figure 4.3). 
A total of 10 individuals from the comparison group participated, ranging in age from 43 
to 81 years (M = 67.82, SD = 11.99). Nine (90%) participants were in stage III CKD, and one 
was (10%) stage IV CKD (see Figure 4.1). Three (30%) participants were male and seven 
(70%) were female (see Figure 4.2). For race, six (60%) were “white/not Hispanic”, two (2%) 
were “black or AA/not Hispanic”, one was (1%) “Asian/not Hispanic”, and one (1%) was “not 
available” (see Figure 4.3). 
A chi-square test of independence was calculated comparing the frequency of race 
between the non-intervention and intervention groups. A significant difference between the 
groups was not found (x2(5) = 4.23, p = .517). Race between the non-intervention group and 
intervention group appear to come from similar population proportions. 
Testing chi-square of independence for gender between the non-intervention group and 
intervention group did not show a significant difference (x2(1) = .92, p = .337). Gender between 
the groups appears to have the same population proportion. 
Comparing the frequency of stage of CKD, a chi-square test of independence did not 
result in a significant difference between the stages (x2(3) = .1.24, p = .745). Non-intervention 
and intervention participants were not significantly different based on stage of CKD. 
An independent-samples t test comparing the mean ages of the non-intervention and 
intervention groups did not find a significant difference between groups (t(41) = .965, p = .34). 
The mean of the non-intervention group (M = 71.53, SD = 10.67) was not significantly different 
from the mean of the intervention group (M = 67.82, SD = 11.99). Figure 4.4 provides a 
visualization of age distribution between the two groups. 
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Table 4.1 
Participant Characteristics 
  
Characteristics of:           Non-intervention Group (n=32)                    Intervention Group (n=10) 
                                                          n                 %                                                  n                 % 
  
Stage of CKD 
 III 25  78 9 90 
 IV 5 16 1 10 
 V 1 3 
 V with transplant 1 3 
Gender 
 Female 15 47 7 70 
 Male 17 53 3 30 
Race/Ethnicity 
 Not Available 3 9.4 1 10 
 White/not Hispanic 18 56.3 6 60 
 Black or African 
 American/not Hispanic 9 28.1 2 20 
 Black or African 
 American/Not Available 1 3.1  
 Other/not Hispanic 1 3.1 
 Asian/not Hispanic  1 10 
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Figure 4.1 
Comparison of Stage of CKD Between Groups 
Figure 4.2 
Comparison of Gender Between Groups 
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Figure 4.3 
Comparison of Race Between Groups 
 
Figure 4.4 
Comparison of Age Between Groups 
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Changes in Outcomes  
Statistical Testing and Significance  
To determine changes in outcomes, data were analyzed via SPSS, version 25. Primary 
and secondary outcomes were analyzed. First, participant healthcare utilization was compared 
between the non-intervention group and intervention group utilizing an independent t test. 
Second, participant healthcare utilization was compared within the same group, pre-intervention 
vs post-intervention, utilizing a paired t test. Description of outcomes, along with tables/figures 
detailing data, are explained. 
The secondary outcome, satisfaction of care, was evaluated by analyzing the responses 
to 12 questions within the “Satisfaction of Care” survey (see Appendix), calculating a mean 
score for current use and future use themed questions. Answers in this survey also provide 
further insight for use of the mobile app. 
Other data were analyzed to determine if this mobile application had an effect on BP and 
weight. These biometric markers were collected pre-intervention, and then weekly for twelve 
weeks. Line graphs of systolic bp, diastolic bp, and weight were utilized to show a trend over 
time during the use of the mobile app. The line graphs also depicted group BPs related to a 
target BP for CKD patients. 
Findings 
 In this EBP project, among patients with moderate to severe CKD, this mobile app 
(CARELogiQ) was effective to self-manage symptoms in order to reduce healthcare utilization 
and increase patient satisfaction with care compared to non-intervention over a four-month 
period. 
 Primary outcome. An independent-samples t test, which compares the means of two 
unrelated samples (Cronk, 2018), was planned to assess for changes in the primary outcome. 
Out of the 32 participants in the non-intervention group, three had a total of four instances of 
healthcare utilization. There were zero instances of healthcare utilization in the intervention 
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group. An independent-samples t test comparing the mean healthcare utilization of the non-
intervention and intervention groups did not find a significant difference between groups (t(40) = 
.930, p = .36). The mean of the non-intervention group (M = 0.125, SD = 0.42) was not 
significantly different from the mean of the intervention group (M = 0.00, SD = 0.00). While there 
was not a statistical difference, the absolute number of HU was fewer in the intervention group 
than the non-intervention group. 
A single-sample t test, which compares means within a single sample (Cronk, 2018) was 
intended to analyze the interventional group both pre-mobile app use and post-mobile app use. 
However, the interventional group did not have healthcare utilization pre- nor post-app use. Due 
to the lack of variance in scores within the group, the planned testing could not be utilized 
(Cronk, 2018). 
 Secondary outcomes. Secondary outcome assessment included measurement of 
participant satisfaction of care while utilizing CARELogiQ. The satisfaction survey was 
developed to evaluate satisfaction with current use of CARELogiQ and to explore features 
desired for future use of the app.  
 Satisfaction with mobile app. The 12-question satisfaction of care survey presented at 
the conclusion of the four-month EBP project aided in evaluating what participants thought 
about the mobile app (see Table 4.2). Four questions on the survey asked participants about 
their reporting of symptoms in the app. Three participants reported symptoms in the mobile app, 
with next day or less response time from the physician. One participant did not receive a 
response. Of the three participants, satisfaction with physician response time resulted in 
participants being “very satisfied” (M = 5, SD = 0, n = 2) with physician response time. 
Questions five and six were specific to education and asked if participants were satisfied with 
the Kidney Smart© class and if they thought it would be helpful to receive educational 
information through the app. Participants more than agreed that the Kidney Smart© class was 
satisfactory (M = 4.6, SD = 0.548, n = 5). Participants more than agreed that receiving 
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educational information through the app would be helpful (M = 4.33, SD = 0.71, n = 9). Question 
seven and eight addressed biometric reporting and asked if participants were satisfied with 
weekly BP and weight reports to the project leader and would it be helpful to report weekly BPs 
and weights through the app. Participants were more than satisfied with reporting weekly 
biometrics to the project leader (M = 4.67, SD = 0.5, n = 9). Participants more than agreed that it 
would be helpful to input biometrics into the app (M = 4.67, SD = 0.5, n = 9). Questions nine and 
ten addressed targeted reminders. Participants were more than satisfied inputting appointment 
times into the app (M = 4.75, SD = 0.46, n = 8). Participants agreed that receiving medication 
reminders through the app would be helpful (M = 3.22, SD = 1.79, n = 9). Question 11 evaluated 
the overall satisfaction with the mobile app. Participants were somewhat satisfied utilizing 
CARELogiQ (M = 3.6, SD = 1.14, n = 9). Suggestions to add to or change in the mobile app 
were solicited in question 12. Two common themes emerged; increase functionality of the app 
and improve communication through the app. 
 Current use. Questions five, seven, nine and 11 evaluated current use of the mobile 
app regarding education, biometric reporting, reminders, and overall mobile app utilization. 
Participants were asked to rate their level of satisfaction utilizing a Likert scale of strongly 
disagree (1) to strongly agree (5). Figure 4.5 illustrates the findings. Overall, participants 
appeared to be satisfied with current use of the mobile app. 
 Future use. Questions six, eight, and 10 evaluated future use of the mobile app 
regarding education, biometric reporting, and reminders. Participants were asked to rate their 
level of satisfaction utilizing a Likert scale of strongly dissatisfied (1) to strongly satisfied (5). 
Figure 4.6 illustrates the findings. Participants appeared to be satisfied with the opportunity of a 
future use of the app to provide education and the ability to record weekly biometric data. The 
mean response to participant satisfaction with future use of reminders was somewhat satisfied. 
 Blood pressure and weight control. This EBP project also afforded the opportunity to 
track weekly BP and weight. According to the NKF (2010), a target BP for CKD patients is 
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recommended below 130/80mmHg to slow progression of CKD. A line graph was used to 
exemplify BPs over the 12-week intervention period (see Figures 4.7 and 4.8). As 
demonstrated, most systolic BP readings were above the recommended 130mmHg line, with 
approximately three participant systolic BPs below the recommending reading. Abnormally 
elevated BPs were reported to the nephrologist for medical evaluation. 
Diastolic BPs demonstrated the majority of readings were below the 80mmHg 
recommended threshold; however, three participants were consistently above this threshold. 
Weekly weights were the most consistent of the readings (see Figure 4.9). As seen in 
the figure, three participants are at or above 250 pounds. It is reasonable to suggest that these 
participants are obese. The majority (70%) of participants fall below 200 pounds. Height and 
BMI were not collected, so this graph does not evaluate obesity, but illustrates the consistency 
of weights. Rapid weight changes in CKD can signify a problem with fluid balance and edema 
(NKF, 2010). None of the participants required treatment due to rapid weight gain or loss.   
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Table 4.2 
Satisfaction Survey for the Mobile App Usage 
  
Question                                                                                           M SD 
  
  Current Usage 
 
5. How satisfied were you with the       
    Kidney Smart© education class? (n = 5)     4.6   0.55 
7. How satisfied were your with reporting your blood    
    pressure and weight to the project leader every week? (n = 9)  4.67  0.5 
9. How satisfied were you with adding your upcoming    
    appointments to the mobile application for appointment 
    reminders? (n = 8)        4.75  0.46 
11. Overall, how satisfied were you with the mobile  
    application? (n = 5)        3.6  1.14 
 
     Future Usage 
 
6. It would be helpful to receive educational information  
    through the app. (n = 9)       4.33  0.71 
8. It would be helpful to be able to add your blood pressure  
    and weight into the app on a weekly basis. (n = 9)   4.67  0.5 
10. It would be helpful to receive medication reminders  
    through the app. (n = 9)       3.22  1.79 
  
MOBILE APPLICATION IN CKD POPULATION 
 
41 
Figure 4.5 
Satisfaction of Current App Use 
 
Figure 4.6 
Agreement of Future App Use 
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Figure 4.7 
Intervention Group Systolic BP Trend 
 
Figure 4.8 
Intervention Group Diastolic BP Trend 
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Figure 4.9 
Intervention Group Weight Trend 
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CHAPTER 5 
DISCUSSION 
This EBP project set out to evaluate the effectiveness of a mobile app to facilitate 
symptom management in order to increase patient satisfaction and decrease healthcare 
utilization. In this chapter, the data from Chapter 4 will be interpreted, along with an evaluation 
of the EBP framework, strengths and weaknesses of the EBP project, and implications for future 
use related to clinical practice, theory, research, and education. 
Explanation of Findings 
 The primary outcome evaluated in this EBP project was measuring healthcare utilization 
after use of CARELogiQ. As seen in the preceding literature (Alessa et al., 2018, Jeddi et al., 
2017, Kitsiou et al., 2017, Lee et al., 2018, Marcolino et al., 2018, and Whitehead & Seaton, 
2016), common themes of communication, reminders, telemonitoring, and education were 
utilized to improve symptom management, resulting in decreased healthcare utilization. While 
not statistically significant, the decrease in healthcare utilization in the intervention group is of 
clinical significance. The secondary outcome evaluated participant satisfaction using 
CARELogiQ. Consistent with Alessa et al. (2018) and Lee et al. (2018), participants were 
satisfied using CARELogiQ in this EBP project. 
Applicability of the EBP Framework 
 The step-by-step approach of the Stetler model facilitated the implementation of this 
project (Stetler, 2001). The initial step of the model, preparation, began by guiding the 
identification of a problem requiring change. The development of a mobile app, and subsequent 
request to launch, spurred the review of the literature. It was then established that high 
healthcare costs, negative health outcomes, and poor quality of life from CKD (Donald et al., 
2018) led to the question whether employment of a mobile app to manage symptoms could 
decrease unscheduled healthcare utilization. A PICOT question was developed, and a search 
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strategy was prepared seeking the highest levels of evidence to support this project. The 
validation phase of the model guided the evaluation and appraisal of the evidence, resulting in a 
determination of fit for use and leading to the comparative evaluation/decision-making phase. 
Synthesis of the evidence and evaluation of commonalities were completed, generating best 
practice recommendations. A decision was made to employ the recommendations to change 
practice by utilizing the mobile app to aid participants in self-management of CKD. The 
translation/application phase was fulfilled by formulating a detailed plan of change and acting 
upon that plan in the practice setting. Lastly, the evaluation phase was comprised of evaluating 
the outcome data to determine if the practice change led to meeting the outcome goals of 
increased patient satisfaction and reduced healthcare utilization. 
 The Stetler model allowed for an ease-of-use implementation of this project by utilizing a 
step-by-step approach. The Stetler model was advantageous as a framework due to possessing 
the flexibility to integrate research into practice on both a formal and informal level, as well as 
individually or organizationally (Stetler, 2001). The highest evidence was formally integrated in 
this project as evidenced by a formal change in office procedure for project participants. Due to 
the project leader implementing the majority of the project, this practice change was more 
individually applied.  
The first phase of the model allowed for consideration of external factors to influence 
identification of EBP activities (Stetler, 2001). The developer of CARELogiQ was a major 
influence in pursuing this EBP project. Another strength of this model was the ability to accept or 
reject evidence based on clinical significance, rather than the strength of the evidence (Phase 2) 
(Stetler, 2001). Due to inclusion of qualitative studies, one systematic review discussed in 
Chapter 2 was not as strong as other evidence utilized in this project, but the clinical 
significance of the evidence contributed to the overall support of this project. In addition, some 
evidence was not specific to CKD, but to chronic disease. This evidence was determined to be 
vital to this project, and included based on “fit of setting”, or the similarity of the sample and 
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study environment to the project population and setting (Stetler, 2001). In the decision-making 
phase (Phase IV), decisions on what evidence to use or how to utilize evidence are practitioner-
level decisions (Stetler, 2001). The project leader extrapolated the components of best practice 
from the literature and developed individual vehicles to employ components to complement the 
current functionality of the app. Education was delivered via the Kidney Smart© classes, 
reminders were delivered via weekly phone calls, and telemonitoring was obtained through 
weekly phone calls. The fourth phase of the model allows for consideration of need for 
appropriate, reasoned variation (Stetler, 2001). This allowed for changes to the inclusion 
criteria, including the change from smartphone to smart device and opening participation to 
patients in a second practice location. In the final phase, Stetler (2001) allows for a “consider 
use” option. While the outcome of this project did not yield statistically significant results, 
stakeholders can “consider use” by making alterations to the project based on project findings 
and recommendations, and implement a pilot project. 
 A limitation of the Stetler model was the dependence on the competency, knowledge, 
and skill level of the project leader. Without these characteristics, research application is 
vulnerable to not being appropriate, effective or evidence-based (Stetler, 1994). While the 
comprehensive step-by-step approach is a strength of the model, the project leader found the 
complexity of details in each step overwhelming and a weakness due to the amount of time 
spent attempting to comprehend the intricacies of these details. 
Strengths and Limitations of the DNP Project 
 Strengths and weaknesses were identified upon evaluation of this EBP project. While 
high level, high quality evidence directed the implementation of this project, due to functionality 
not yet employed by the app, some limitations were identified. A more detailed discussion of 
strengths and weakness is continued below. 
Strengths 
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 Strengths of this project included strong evidence to support the practice change. The 
higher the level and quality of the evidence, the stronger the recommendation represents best 
practice (Dang & Dearholt, 2017). Most of the literature reviewed was level I (Jeddi et al., 2017, 
Lee et al., 2018, and Whitehead & Seaton, 2016) and level II (Kitsiou et al., 2017, and Marcolino 
et al., 2018), with one level III piece of evidence (Alessa et al., 2018) that was deemed of high 
clinical significance. All evidence was of high quality (Alessa et al., 2018, Jeddi et al., 2017, 
Kitsiou et al., 2017, Lee et al., 2018, Marcolino et al., 2018, and Whitehead & Seaton, 2016). 
These characteristics led to concrete recommendations to guide the practice change. The EBP 
model, Stetler, was another strength of this EBP project. The step-by-step approach of this 
model provided a concrete framework to develop this project. It was also advantageous to have 
an invested project facilitator who was supportive of a successful EBP project implementation. 
The site facilitator, the nephrologist who developed the CARELogiQ app, championed its use in 
this EBP project. Having access to the mobile app creator allowed for ease of access to 
answers regarding the functions of the mobile app. The practice of this nephrologist provided a 
setting conducive to a successful project. The office staff was invaluable for accessing patient 
information in the EMR system. 
Best practice recommendations derived from the literature included communication 
(Alessa et al., 2018, Jeddi et al., 2017, Kitsiou et al., 2017, Lee et al., 2018, Marcolino et al., 
2018, and Whitehead & Seaton, 2016), reminders (Alessa et al., 2018, Jeddi et al., 2017, 
Kitsiou et al., 2017, and Marcolino et al., 2018), telemonitoring (Alessa et al., 2018, Jeddi et al., 
2017, Kitsiou et al., 2017, Lee et al., 2018, and Marcolino et al., 2018), and education (Alessa et 
al., 2018, Jeddi et al., 2017, Kitsiou et al., 2017, Lee et al., 2018, and Marcolino et al., 2018) 
with an app. CARELogiQ provided a platform for participants to report symptoms through the 
app, without needing to contact the office. This process of reporting symptoms allowed for direct 
communication with the nephrologist, compared to current office procedure of office staff writing 
down a patient message and attaching it to a clipboard to be reviewed at the end of the day. 
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The communication feature also gave participants more control over how symptoms were 
reported to the nephrologist, by having participants answer questions of duration and severity 
within the report. There was no need to rely on office staff to transcribe and report an accurate 
message from the participant. 
While telemonitoring relied on weekly, manual checks of BP and weights, the collection 
of these recordings benefitted participants. Several participants were identified by the project 
leader as having abnormal BP readings that required medication adjustments. These checks 
resulted in participants having closer attention given to the management of their BP between 
office visits. This project also identified a trend in the majority of participants’ systolic BPs being 
above the recommended value for CKD. The telemonitoring component of best practice can be 
enhanced with the addition of a device to link to CARELogiQ to directly record and transmit BPs 
and weights, allowing for tighter control of these biometric markers. 
While the education component of best practice recommendations was not yet 
functionable through the CARELogiQ app, the Kidney Smart© education class provided another 
strength to this project. Participants signed up for a 90-minute, group structured class at an 
outside facility, conducted by an outside educator. Participants who attended this class were 
highly satisfied with the information they obtained and benefitted from increased knowledge of 
their disease. Most participants stated they would like an education component within 
CARELogiQ. Incorporation of an educational section in CARELogiQ could potentially provide 
the same level of satisfaction or greater, which may result in better self-management of their 
CKD. 
This EBP project also identified another patient care issue that could be improved. As 
stated previously, of the 180 patients in this setting with moderate to severe CKD, 37 (21%) did 
not have their race identified. Due to African Americans having higher average muscle mass 
and creatinine generation rate, the GFR of African Americans is higher than non-African 
American patients (NKF, 2014). Reports of GFR not adjusted for African American patients 
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would not accurately reflect the severity of CKD in the African American patient. It is important 
to collect complete demographics, including race, to accurately interpret lab results of patients. 
Limitations 
CARELogiQ was still in development, resulting in all functionality not being available as 
had been projected. Best practice recommendations for this EBP project included use of 
automatic reminders; however, CARELogiQ only allowed for the manual input of upcoming 
appointment dates. It would be beneficial for patients to have upcoming appointments 
automatically populate in the app for accuracy and completeness. Other reminders that would 
have been appropriate to incorporate from the best practice recommendations included 
medication reminders and biometric evaluation reminders. For this project, the project leader 
augmented this concept by reminding participants to enter upcoming appointments in the app, 
to take their medication as scheduled, and to log their BP and weights at least weekly for 
collection of these data in the weekly project leader phone call to participants. Incorporation of 
these features into the CARELogiQ app platform would be potentially beneficial. 
Another limitation of this project was the low number of participants. While the non-
intervention group was based on the number of total patients in the clinic, the intervention group 
was not limited beyond the inclusion/exclusion criteria. Many patients either did not have access 
to a smartphone or tablet, felt uncomfortable using mobile apps, or were not interested in 
participating in the project. When no access to a smartphone was identified as a common 
limitation to enrolling participants, opening up the inclusion criteria to include smart devices, 
such as a tablet was beneficial. Future EBP projects may benefit from office supplied devices 
obtained by funds from a grant. Participants who were uncomfortable with using mobile apps 
were given the opportunity to download CARELogiQ in the office with assistance from the 
project leader, although some potential participants still declined the invitation due to this issue. 
The project leader met patients on the same day that the invitation was extended to participate 
in the project. Patients who stated they just were not interested in participation may have been 
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more willing to participate if the project was introduced to them by staff with whom they already 
had a clinic relationship.  
The timeframe of the project was also a limitation. Initially, only one practice location 
schedule was utilized to invite participants. In an effort to increase the number of potential 
participants, a second practice location’s schedule was added. This site added another half-day 
clinic per week. In total, the nephrologist was scheduled three half-days per week. The limited 
number of office hours, along with the four-month duration of the project may have limited the 
source of potential participants. Evidence used in this project had durations of a few minutes to 
24 months, with most studies identifying durations lasting up to 12 months (Alessa et al., 2018, 
Jeddi et al., 2017, Kitsiou et al., 2017, Lee et al., 2018, Marcolino et al., 2018, and Whitehead & 
Seaton, 2016). Having more scheduled clinics per week to invite participants would potentially 
have resulted in a larger number of participants in the intervention group. 
Overall, the lack of functionality of the mobile app resulted in limitations of the project. 
While the mobile app allowed participants to report their symptoms to their provider through the 
mobile app, two-way messaging through the mobile app was not possible. Participants were 
able to manually input upcoming appointments into the mobile app, but appointments did not 
automatically populate in the mobile app at the time an appointment was scheduled. 
Participants were also frustrated by difficulty signing up for the initial app usage. Some 
participants were able to sign up, but then unable to sign in to the app after previously being 
able to do so. To overcome the limitations of the mobile app, the project leader called 
participants weekly by phone to collect BP and weight readings. It was not possible to collect 
these data by text messaging, through the mobile app, or by a direct telemonitoring device 
connected to the smartphone or tablet. The mobile app also lacked the ability to store these 
biometric readings. Lastly, the mobile app did not provide a platform for participants to receive 
any direct educational information, either through links to outside sources, or educational 
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references within the mobile app. The addition of these features would be an added benefit to 
patients to review educational materials at any time.  
Implications for the Future 
Practice 
 Utilizing CARELogiQ to self-manage symptoms may be effective to reduce healthcare 
utilization and increase patient satisfaction of care. Providers can use CARELogiQ to empower 
patients to be more self-sufficient. Patients would have more control over management of their 
CKD. By reporting symptoms directly into the app, providers would be able to receive 
information in real time, allowing for the provider to determine the level of urgency requiring a 
response. Internalizing telemonitoring functionality could provide greater control over BP and 
weight between office visits. Storing biometric data in the app could allow for easy review of 
biometric trends during office appointments. The data gathered in this project have 
demonstrated a trend of systolic BPs higher than the recommended value. Providers could use 
this app to aid in the normalization of BPs. Appointment reminders could reduce the amount of 
missed appointments, and reminders for medication and biometric evaluations could improve 
care as well by serving as a reminder to take scheduled medications and check BPs and 
weights. The education component of the app could compliment and reinforce the educational 
information the provider is giving to the patient during office visits. The app could provide “tabs” 
for education within the app, links to other sources of education outside the app, and provide 
resources for additional education such as Kidney Smart©. With increased functionality, 
CARELogiQ has the potential to aid providers in the management of CKD. It may also be 
beneficial to have advanced practice registered nurses as dedicated CARELogiQ navigators, 
managing patient care through the CARELogiQ app within the institution implemented. 
Model/Framework/Theory 
 The Stetler model provided a concrete framework for this EBP project. This model 
provided a step-by-step approach to guide this project through the five phases, with the ability to 
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loop back to previous phases as needed to allow for variations. Projects that are implemented 
mainly by an individual project leader are well-suited for this model. This model also encourages 
clinically significant evidence to be considered in addition to evidence graded as strong. Future 
EBP projects would benefit from using the Stetler model as an EBP framework for similar 
projects due to the guidance through each step from identification of a problem, review of the 
literature, synthesis of the evidence, implementing the plan, and evaluation of the project. 
Further guidance could be attained by the addition of a theoretical framework. Although this 
EBP project did not utilize a theoretical framework, several theories may be of assistance in 
future EBP projects. 
Research 
 While the findings of the primary outcome of this project were not statistically significant, 
this EBP project can contribute to future research and future EBP projects. This EBP project is 
the first to evaluate use of CARELogiQ. Strengths and limitations of the project can be utilized to 
make changes to the app functionality and design of a future EBP project. A pilot project could 
also be implemented based of the results of this EBP project, potentially leading to statistically 
significant findings, allowing for commercial use of CARELogiQ.  
Education 
 This EBP project highlighted some important areas of needed education. Staff should be 
educated on the need to identify race in all demographic data collected on patients. Access to 
this demographic data is imperative to accurately diagnose the stage of CKD for individual 
patients and monitor their clinical progress.  
 For patients, the education component that could be built into CARELogiQ would be 
beneficial by having information about their disease at their fingertips. The mobile app could 
also provide a resource link for additional education opportunities. Attendance of Kidney 
Smart© classes should continue to be strongly encouraged.  
Conclusion 
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 The purpose of this project was to initiate the use of CARELogiQ in an outpatient CKD 
clinic to positively affect CKD self-management resulting in increased patient satisfaction of care 
and decreased hospitalizations and ER visits. While healthcare utilization did decrease in the 
intervention group, this was not statistically significant. Having a larger intervention sample size, 
in addition to a longer duration of time to invite participants, may have contributed to significant 
outcomes.  
 In response to the secondary outcome, patients were satisfied using CARELogiQ, 
although attenuated by lack of some available functions and trouble with logging into the app. 
With further development of CARELogiQ, patient satisfaction could only be improved with 
increased functionality of the mobile app. Future CARELogiQ EBP projects may lead to 
significant outcomes with a larger sample size, a longer implementation time, added 
functionality of CARELogiQ, and a smart device provided to participants who did not have their 
own device. By improving symptom management, CARELogiQ could reduce HU, leading to a 
positive impact on CKD burden. 
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ACRONYM LIST 
BG: Blood Glucose 
BP: Blood Pressure 
CINAHL: Cumulative Index of Nursing and Allied Health 
CKD: Chronic Kidney Disease 
CVD: Cardiovascular Disease 
DM: Diabetes 
GFR: Glomerular Filtration Rate 
HCP: Health Care Provider 
HF: Heart Failure 
HTN: Hypertension 
JBI: Johana Briggs Institute 
JHNEBP: Johns Hopkins Nursing Evidence-Based Practice Research Evidence Appraisal Tool 
KDIGO: Kidney Disease Improving Global Outcomes Initiative 
KDOQI: Kidney Disease Outcomes Quality 
mHealth: Mobile Technology 
NKF: National Kidney Foundation 
PDA: Personal Digital Assistant Devices (PDAs) 
SMS: Short Message Service 
US: United States 
USRDS: United States Renal Data System 
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APPENDIX  
Satisfaction of Care Survey 
SATISFACTION OF CARE SURVEY 
Thank you for your time and effort to participate in our project. Please answer the questions 
below as best you can. The information will be helpful for future developments of the app. If the 
question does not apply to you, just answer “NA”. Your answers will be anonymous. 
 
1. Approximately, how many times did you report symptoms in the mobile application?  
2. What symptom(s) did you report? 
3. How long did it take to get a call back for your reported symptom(s)? 
4. The length of time it took for a response to your reported symptoms was satisfactory. SD, 
D, N, A, SA or NA  
5. The Kidney Smart© education class was satisfactory.  SD, D, N, A, SA or NA  
6. It would be helpful to receive educational information through the app. SD, D, N, A, SA 
7. How satisfied were you with reporting your blood pressure and weight to the project 
leader every week? SD, D, N, S, VS  
8. It would be helpful to be able to add your blood pressure and weight into the app on a 
weekly basis. SD, D, N, A, SA 
9. How satisfied were you with adding your upcoming appointments to the mobile 
application for appointment reminders? VD, D, N, S, VS 
10. It would be helpful to receive medication reminders through the app. SD, D, N, A, SA 
11. Overall, how satisfied were you with the mobile application. VD, D, N, S, VS 
12. Do you have any suggestions to add to or change in the mobile application? 
 
 
 
